
Clinical TrialNov 17, 2026, 05:35 PM
Inhibrx: Ozekibart Combo Shows 62.7% ORR in Ewing Sarcoma Trial
AI Summary
Inhibrx Biosciences, Inc. announced updated clinical data from its Phase 1/2 expansion study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide for relapsed or refractory Ewing sarcoma. The data, to be presented at the Connective Tissue Oncology Society 2026 Annual Meeting, showed a 62.7% overall response rate (ORR) and an 86.3% disease control rate (DCR) in 51 response-evaluable patients. The company plans to advance ozekibart development based on these compelling results.
Key Highlights
- Ozekibart combination achieved 62.7% ORR in relapsed/refractory Ewing sarcoma patients.
- Disease Control Rate (DCR) reached 86.3% with durable responses observed.
- Among 51 response-evaluable patients, 32.7% had complete or partial responses.
- Median Progression Free Survival (mPFS) was 6.0 months.
- Data shows meaningful improvement over historical benchmarks for irinotecan and temozolomide alone.
- The combination demonstrated an acceptable and manageable safety profile.
- The FDA has accepted the biologics license application for ozekibart in conventional chondrosarcoma.
Price Impact
More from INBX